DIGEMID (Peru)

DIGEMID (Dirección General de Medicamentos, Insumos y Drogas) is the Republic of Peru's national regulatory authority responsible for the regulation of human medicines + biologicals + vaccines + medical devices + IVDs + sanitary products + cosmetics + drugs of abuse + controlled substances. DIGEMID operates as a General Directorate of the Ministry of Health (MINSA — Ministerio de Salud) — unlike Chile's ISP or Argentina's ANMAT, DIGEMID does not have institutional autonomy + sits directly within the MINSA central administration. This structural position has both advantages (close integration with public-health policy + Essential Medicines Programme) + disadvantages (less budget + procedural autonomy than peer Latin American regulators).

DIGEMID's organisational structure includes:

• Director General — chief executive appointed by the Minister of Health; serves at the discretion of the Minister.
• Dirección de Productos Farmacéuticos — pharmaceutical product registration + variations + renewals.
• Dirección de Productos Sanitarios — sanitary products (cosmetics, hygiene products, biocides) registration.
• Dirección de Dispositivos Médicos y Productos Sanitarios — medical devices + IVDs registration + post-market.
• Dirección de Autorizaciones Sanitarias — pharmacy + drugstore + manufacturer + importer establishment authorisations.
• Dirección de Inspección y Certificación — GMP + GDP + GCP inspections + certifications.
• Dirección de Fiscalización, Control y Vigilancia Sanitaria — enforcement + market surveillance + counterfeit-medicine investigation.
• Dirección de Farmacovigilancia, Acceso y Uso — pharmacovigilance + tecnovigilancia + cosmetovigilancia + reactivovigilancia + rational drug use.
• Dirección de Drogas Controladas — controlled substances + drugs of abuse + precursor chemicals.
• Equipo Técnico de Asuntos Internacionales — international cooperation + WHO/PAHO + CAN + Pacific Alliance + PANDRH liaison.
• DIRESAs (Direcciones Regionales de Salud) — 25 regional health directorates execute DIGEMID inspections + post-market surveillance at the regional level.
• INS / CENAFyT — Instituto Nacional de Salud operates the Centro Nacional de Control de Calidad (National Quality Control Centre) providing DIGEMID's pharmaceutical + biological + medical-device laboratory services.

DIGEMID is distinct from + complementary to: DIRESAs (regional health directorates executing pharmacy + healthcare-facility licensing + regional inspections); INS — Instituto Nacional de Salud (national health research institute + CENAFyT laboratory operator + reference-laboratory services); SENASA — Servicio Nacional de Sanidad Agraria (veterinary medicines + agricultural inputs + animal-origin foods); DIGESA — Dirección General de Salud Ambiental (environmental health + food sanitary regulation at the national level for industrial-scale food production); SUNAT (customs interface for imported medicines + medical devices); + the Colegio Químico Farmacéutico del Perú (pharmacist professional body).

Legal foundations are Law 29,459 of 2009 (the Law of Pharmaceutical Products, Medical Devices and Sanitary Products — the foundational Peruvian medicines + devices law), Supreme Decree 014-2011-SA (the implementing regulation), Supreme Decree 016-2011-SA (Sanitary Registration Regulation for Pharmaceutical Products), Supreme Decree 010-1997-SA (current Peruvian Pharmaceutical Products Sanitary Regulation as amended), Supreme Decree 017-2006-SA (Pharmacovigilance regulation), DIGEMID Directorial Resolutions establishing GMP + GDP + GCP requirements + a substantial body of DIGEMID technical norms (Normas Técnicas).

DIGEMID is a WHO/PAHO Member State regulator working toward WHO/PAHO Regional Reference Authority status — DIGEMID has been benchmarked against the WHO Global Benchmarking Tool (GBT) + is progressively maturing its regulatory functions. DIGEMID is an active WHO Prequalification Collaborative Registration Procedure (CRP) user (accepting WHO-PQ-approved products through accelerated reliance review), a co-leader of the Andean Community (CAN) Pharmaceutical Harmonisation alongside INVIMA Colombia + ARCSA Ecuador + AGEMED Bolivia (CAN Decisions 418/516/705/824), a co-leader of the Pacific Alliance (Alianza del Pacífico) Health Regulatory Cooperation alongside ISP/ANAMED Chile + INVIMA Colombia + COFEPRIS Mexico, an active PANDRH (Pan American Network for Drug Regulatory Harmonisation) participant + a PIC/S Pre-Accession Applicant. DIGEMID participates in WHO + PAHO regulatory-strengthening initiatives + leverages PAHO Strategic Fund procurement for essential medicines + vaccines.

Peruvian pharmaceutical regulation operates under a layered framework of primary legislation + Supreme Decrees + Ministerial Resolutions + DIGEMID Directorial Resolutions:

• Law 26,842 of 1997 (General Health Law) — foundational Peruvian health legislation covering medicines, devices, sanitary products as a chapter within general health regulation.
• Law 29,459 of 2009 — Law of Pharmaceutical Products, Medical Devices and Sanitary Products — the foundational modern Peruvian medicines + devices law replacing prior fragmented framework.
• Supreme Decree 014-2011-SA — Implementing Regulation of Law 29,459 establishing operational rules for registration, GMP, pharmacovigilance, inspection.
• Supreme Decree 016-2011-SA — Sanitary Registration Regulation for Pharmaceutical Products including biological and biotechnological products.
• Supreme Decree 010-1997-SA — Pharmaceutical Products Sanitary Regulation (as amended; legacy framework partially superseded by 016-2011-SA).
• Supreme Decree 017-2006-SA — Pharmacovigilance Regulation establishing the Sistema Peruano de Farmacovigilancia + Tecnovigilancia.
• Supreme Decree 011-2012-SA — Medical Devices Regulation establishing Class I-IV risk classification + Peruvian Authorised Representative requirements.
• Supreme Decree 016-2013-SA — Cosmetics Regulation substantively aligned with Andean Community Decision 833 + EU Cosmetics Regulation.
• DIGEMID Directorial Resolution 162-2019/DIGEMID — Peruvian Good Manufacturing Practice Manual substantively aligned with WHO TRS 986 Annex 2 + PIC/S GMP Guide + EU GMP + ICH Q7.
• DIGEMID Directorial Resolution 130-2018/DIGEMID — Peruvian Good Distribution Practice Manual substantively aligned with WHO + EU GDP.
• DIGEMID Directorial Resolution 048-2018/DIGEMID — Peruvian Good Clinical Practice Manual substantively aligned with ICH E6(R2).
• DIGEMID Directorial Resolution 354-2021/DIGEMID — Peruvian Pharmacovigilance + Tecnovigilancia framework substantively aligned with ICH E2 + EU GVP.
• Law 28,305 of 2004 + Supreme Decree 044-2006-PCM — Controlled Substances + Precursor Chemicals + Drugs of Abuse Regulation administered by DIGEMID Dirección de Drogas Controladas.
• Andean Community Decisions 418/516/705/824 — directly applicable harmonised pharmaceutical framework across Peru + Colombia + Ecuador + Bolivia (legally binding under CAN supranational law).
• Pacific Alliance Health Regulatory Cooperation Resolutions — harmonised frameworks progressively applicable across Peru + Chile + Colombia + Mexico.

DIGEMID's laboratory functions are operated through INS — Instituto Nacional de Salud (the Peruvian National Institute of Health) which hosts CENAFyT — Centro Nacional de Control de Calidad (National Quality Control Centre). CENAFyT provides DIGEMID's pre-registration quality testing, post-market surveillance testing, lot-release testing for vaccines + biologicals, biological characterisation + counterfeit-medicine forensic analysis. INS also operates Peru's National Reference Laboratories for public-health analytes including vector-borne diseases (CENSI — Centro Nacional de Salud Intercultural), HIV, tuberculosis, foodborne pathogens + zoonotic diseases.

• CENAFyT Pharmaceutical QC — pre-registration + post-market + lot-release testing for medicines, biologicals, vaccines; ISO/IEC 17025 accredited across multiple testing scopes.
• INS Reference Laboratories — public-health reference laboratory services across HIV, tuberculosis, malaria, dengue, leishmaniasis, Chagas disease + emerging-pathogen surveillance.
• WHO PQ-Lab pursuit — CENAFyT is progressively maturing toward WHO Prequalification of Quality Control Laboratories status; not currently WHO PQ-Lab designated.
• Biological characterisation — INS conducts vaccine lot-release testing for ESNI procurement + PAHO Revolving Fund-procured vaccines.
• Counterfeit-medicine forensics — INS/CENAFyT supports DIGEMID Dirección de Fiscalización investigations of counterfeit + substandard medicines in coordination with SUNAT customs + Policía Nacional.
• Public-health toxicology — INS operates Peru's public-health toxicology service including occupational + environmental toxicology + heavy-metal surveillance (particularly relevant for Peruvian mining-region populations).
• GMP Inspectorate base — DIGEMID Dirección de Inspección y Certificación operates GMP inspections of Peruvian + foreign manufacturing facilities; DIGEMID inspectors progressively maturing toward PIC/S standards through PIC/S Pre-Accession process.
• COVID-19 + pandemic response — INS/CENAFyT was a central pillar of Peru's COVID-19 response including PCR + serology testing, genomic surveillance, vaccine lot release.
• Capacity-building — INS hosts training programmes for Andean Community + Pacific Alliance pharmaceutical analysts + contributes to WHO + PAHO regulatory-strengthening initiatives.

DIGEMID medical-device + IVD regulation operates under Supreme Decree 011-2012-SA with a Class I-IV risk-based framework substantively aligned with GHTF/IMDRF + EU MDR. Foreign manufacturers must appoint a Peruvian Authorised Representative.

• Risk-based Classification (Class I / II / III / IV) — substantively aligned with GHTF/IMDRF + EU MDR with Peruvian-specific overlay; IVDs classified under separate DIGEMID framework.
• Registro Sanitario — issued by DIGEMID Dirección de Dispositivos Médicos based on technical-file review + Peruvian Authorised Representative designation + Spanish-language labelling.
• Peruvian Authorised Representative — Peru-resident legal entity required for foreign manufacturers; bears post-market Tecnovigilancia responsibility + DIGEMID regulatory interface.
• ISO 13485:2016 — recognised by DIGEMID as QMS evidence framework; Peruvian-specific overlay required including Peruvian quality records + Representative QMS interface.
• Reliance pathways — DIGEMID accepts CE Mark + FDA 510(k) + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; reliance reduces dossier + accelerates review.
• MDSAP — Peru is not currently an MDSAP Participating Regulator + does not require MDSAP audit reports; however DIGEMID accepts MDSAP reports as supporting evidence + leverages MDSAP-audited manufacturer evidence in inspection planning.
• Andean Community Medical Device Harmonisation — DIGEMID participates in CAN medical-device harmonisation work-streams; reliance + harmonised technical-file requirements progressively expanding across Peru + Colombia + Ecuador + Bolivia.
• Pacific Alliance Medical Device Harmonisation — DIGEMID participates in Pacific Alliance medical-device harmonisation work-streams; reliance progressively expanding across Peru + Chile + Colombia + Mexico.
• Post-market Tecnovigilancia — DIGEMID operates medical-device adverse-event reporting through the Peruvian Tecnovigilancia system; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• Cosmetic Notification — cosmetics under Supreme Decree 016-2013-SA + Andean Community Decision 833 require Notificación Sanitaria Obligatoria (NSO) + Spanish-language labelling; INCI-aligned ingredient listing + safety substantiation + cosmetovigilance reporting.
• Peruvian UDI — DIGEMID is progressively implementing UDI requirements substantively aligned with FDA UDI + EU EUDAMED UDI; Peruvian-specific overlay applies.
• Importation Permit — DIGEMID Importation Permit required in addition to product registration for foreign-manufactured devices entering Peru via SUNAT customs.

DIGEMID operates the Sistema Peruano de Farmacovigilancia y Tecnovigilancia (SPFyT) under Supreme Decree 017-2006-SA + DIGEMID Directorial Resolution 354-2021/DIGEMID. The Peruvian pharmacovigilance system integrates national + regional + hospital + community-pharmacy + manufacturer reporting through DIGEMID-managed VigiFlow-Peru platform + leverages WHO PIDM membership since 2002.

• Sistema Peruano de Farmacovigilancia y Tecnovigilancia — coordinated national pharmacovigilance + tecnovigilancia programme with effector centres at major hospitals + DIRESAs + EsSalud (Social Security health system) + Sanidad de las Fuerzas Armadas (Armed Forces health system) + Sanidad PNP (National Police health system) + Marketing Authorisation Holders.
• WHO PIDM Member — Peru is a WHO Programme for International Drug Monitoring member (since 2002) + contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC).
• VigiFlow-Peru — DIGEMID operates VigiFlow-Peru online ADR reporting platform (WHO UMC VigiFlow-based); available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — DIGEMID accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); DIGEMID-specific submission timeline.
• Risk Management Plans (RMP) — DIGEMID requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — DIGEMID operates targeted active-surveillance programmes including for HIV antiretrovirals + tuberculosis + COVID-19 vaccines + biologicals.
• ESAVI (Eventos Supuestamente Atribuibles a Vacunación e Inmunización) — Peruvian vaccine adverse-event surveillance system aligned with PAHO ESAVI methodology; central to ESNI safety monitoring + PAHO Revolving Fund vaccine surveillance.
• Tecnovigilancia + Cosmetovigilancia + Reactivovigilancia — DIGEMID operates parallel materiovigilance for medical devices + cosmetics + IVDs.
• High-altitude + indigenous-population pharmacovigilance — DIGEMID + INS conduct targeted ADR surveillance in high-altitude (Andean) + Amazonian indigenous populations recognising distinctive pharmacokinetic + cultural factors.

• WHO Global Benchmarking Tool — DIGEMID has been benchmarked against WHO GBT + is progressively maturing toward WHO/PAHO Regional Reference Authority designation; substantial regulatory-strengthening investment ongoing.
• WHO PQ CRP Active User — DIGEMID is an active WHO Prequalification Collaborative Registration Procedure (CRP) user accelerating WHO-PQ-approved medicines + vaccines into Peru; CRP route substantially reduces review timeline.
• PAHO Revolving Fund — DIGEMID coordinates with PAHO Revolving Fund for vaccine + essential-medicine procurement; PAHO-procured products accelerated through DIGEMID under PAHO Strategic Fund framework.
• Andean Community Co-Leader — DIGEMID is a co-leader of Andean Community (CAN) Pharmaceutical Harmonisation alongside INVIMA Colombia + ARCSA Ecuador + AGEMED Bolivia; CAN Decisions 418/516/705/824 are directly applicable under CAN supranational law.
• Pacific Alliance Co-Leader — DIGEMID is a co-leader of Pacific Alliance Health Regulatory Cooperation alongside ISP/ANAMED Chile + INVIMA Colombia + COFEPRIS Mexico.
• PANDRH Active Participant — DIGEMID is an active PANDRH participant alongside FDA + Health Canada + ANVISA + COFEPRIS + ANMAT + INVIMA + ISP.
• PIC/S Pre-Accession Applicant — DIGEMID has commenced PIC/S Pre-Accession process; PIC/S Membership would mark a transformational maturation of Peruvian GMP practice + open reliance routes globally.
• ICH Observer — DIGEMID engages with ICH guidelines; ICH guidelines extensively implemented in Peruvian regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• Bilateral MoUs — DIGEMID holds MoUs with FDA + EMA + Health Canada + ANVISA + COFEPRIS + INVIMA + ANMAT + ISP + ARCSA + AGEMED + Uruguayan MSP + Paraguayan DNVS + Cuban CECMED + Spain AEMPS.
• ICDRA Participant — active International Conference of Drug Regulatory Authorities participant.
• APEC LSIF — DIGEMID participates in Asia-Pacific Economic Cooperation Life Sciences Innovation Forum (LSIF) Regulatory Harmonisation Steering Committee.
• OECD GLP MAD Observer — Peru engages with OECD Mutual Acceptance of Data framework as Observer.
• Industry Cooperation — DIGEMID engages with ADIFAN (Asociación de Industrias Farmacéuticas Nacionales — domestic generic manufacturers) + ALAFARPE (Asociación Nacional de Laboratorios Farmacéuticos — research-based / multinational manufacturers).

• Peruvian Authorised Representative not properly designated — application rejected at DIGEMID intake or post-approval compliance failure.
• Spanish-language labelling deficiencies — Spanish (Peruvian variant) labelling + Spanish PIL (inserto / prospecto) required; many applicants provide other Latin American Spanish variants without Peruvian-specific terminology + climate-appropriate storage conditions.
• GMP DIGEMID Directorial Resolution 162-2019/DIGEMID gaps — applicants assuming EU GMP / PIC/S GMP compliance is automatically sufficient without addressing Peru-specific DIGEMID Manual clarifications + Peruvian-specific quality records.
• Peruvian climate-zone stability data missing — Peru spans Climate Zone IVa (hot humid coastal + jungle Amazonas + selva), Climate Zone II (temperate Andean highlands + sierra) + Climate Zone I (cold high-altitude Andean peaks + altiplano above 3,500m); many applicants provide insufficient zonal-specific stability data + ignore high-altitude packaging considerations.
• Andean Community CAN reliance not leveraged — CAN Decisions 418/516/705/824 directly-applicable harmonised framework underutilised by applicants targeting multiple CAN markets through DIGEMID + INVIMA + ARCSA + AGEMED coordination.
• Pacific Alliance reliance not leveraged — Pacific Alliance Health Regulatory Cooperation underutilised by applicants targeting multiple Pacific Alliance markets through DIGEMID + ISP + INVIMA + COFEPRIS coordination.
• WHO PQ CRP reliance under-utilised — WHO-PQ-approved products eligible for accelerated DIGEMID CRP review; DIGEMID is an active CRP user.
• PAHO Revolving Fund route not leveraged — PAHO Strategic Fund + Revolving Fund procurement provides registration acceleration + reduced documentation burden for essential medicines + vaccines.
• SENASA jurisdictional split — veterinary medicines + agricultural inputs + animal-origin foods sit with SENASA, not DIGEMID; avoid filing veterinary or animal-origin food applications to DIGEMID.
• DIGESA jurisdictional split — industrial food production sanitary regulation sits with DIGESA, not DIGEMID; DIGEMID focuses on medicines + medical devices + sanitary products (cosmetics, hygiene, biocides).
• DIRESA regional scope — pharmacy practice + pharmacy premises licensing + healthcare-facility regional licensing sit with DIRESAs (Direcciones Regionales de Salud), not central DIGEMID; DIGEMID focuses on national product regulation.
• Vital-need / high-cost pathway not leveraged — MINSA + DIGEMID vital-need + high-cost-disease pathway underutilised; provides regulatory acceleration + SIS + EsSalud coverage acceleration for eligible products.
• Variations strategy not planned — variations procedure substantively similar to WHO but with Peru-specific timelines + fee structure + Spanish-language requirements.
• Renewal timing missed — 5-year Registro Sanitario renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Clinical trial DIGEMID DR 048-2018/DIGEMID + REPEC steps — Peruvian clinical trials require DIGEMID CTA + INS-recognised Research Ethics Committee approval + REPEC (Peruvian Clinical Trials Registry) listing; sponsors sometimes overlook REPEC + indigenous-community consent for Andean + Amazonian populations under ILO 169 Convention obligations.

V5 Ultimate provides the operational infrastructure Peruvian + foreign-supplier sites need for Law 29,459 + Supreme Decree 014-2011-SA + 016-2011-SA + DIGEMID Directorial Resolution 162-2019/DIGEMID GMP + DIGEMID Medical Devices framework + Andean Community + Pacific Alliance + WHO PQ CRP + Sistema Peruano de Farmacovigilancia + vital-need pathway readiness.

• DIGEMID GMP control framework — WHO TRS 986 Annex 2 + PIC/S + EU GMP + ICH Q7-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Peru-specific clarifications + Peruvian climate-zone IVa/II/I stability monitoring + high-altitude packaging considerations.
• DIGEMID drug-registration packaging — Peruvian CTD-aligned dossier structure with Peru Module 1 specifics + Module 3 stability + Peruvian inserto / prospecto + Spanish (Peruvian variant) labelling + Authorised Representative declarations + Supreme Decree 016-2011-SA framework + bioequivalence evidence under phased framework.
• Andean Community workflow — CAN Decisions 418/516/705/824 directly-applicable packaging for joint registration across Peru + Colombia + Ecuador + Bolivia; DIGEMID + INVIMA + ARCSA + AGEMED coordination.
• Pacific Alliance workflow — Pacific Alliance Health Regulatory Cooperation packaging for harmonised registration across Peru + Chile + Colombia + Mexico; DIGEMID + ISP + INVIMA + COFEPRIS coordination.
• PANDRH workflow — PANDRH reliance pathway packaging for products assessed by FDA + Health Canada + ANVISA + COFEPRIS + ANMAT + INVIMA + ISP Reference Authorities.
• WHO PQ CRP workflow — applicant-side WHO PQ CRP packaging with reduced dossier + accelerated DIGEMID review.
• PAHO Revolving Fund workflow — PAHO Strategic Fund + Revolving Fund essential medicine + vaccine procurement packaging with accelerated DIGEMID coordination.
• Vital-need + high-cost workflow — MINSA + DIGEMID vital-need + high-cost-disease pathway packaging with SIS + EsSalud coverage acceleration.
• Peruvian Authorised Representative workflow — foreign-manufacturer Representative designation + role-management + Peru-specific post-market surveillance + DIGEMID interface.
• Peruvian clinical-trial workflow — DIGEMID DR 048-2018/DIGEMID GCP + INS-recognised REC + REPEC registry + Peruvian SUSAR reporting via VigiFlow-Peru + indigenous-community consent under ILO 169.
• DIGEMID Pharmacovigilance + VigiFlow-Peru integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Spanish-language ICSR + Sistema Peruano de Farmacovigilancia coordination + VigiFlow-Peru submission + VigiBase upload + Risk Management Plan packaging + ESAVI vaccine adverse-event reporting.
• Tecnovigilancia + Cosmetovigilancia + Reactivovigilancia workflow — parallel materiovigilance + cosmetovigilance + IVD-vigilance packaging.
• Medical-device + cosmetic + IVD workflow — Supreme Decree 011-2012-SA + Supreme Decree 016-2013-SA + CAN Decision 833 dossier packaging + Class I-IV classification + ISO 13485 + Peruvian Authorised Representative + post-market Tecnovigilancia.
• DIGEMID Variations workflow — variations classification + DIGEMID procedure + Peruvian packaging.
• Renewal workflow — 5-year Registro Sanitario renewal window tracking + DIGEMID procedure packaging.
• Andean + Pacific Alliance regional bridging — for companies operating across Latin America, V5 surfaces DIGEMID + INVIMA + ARCSA + AGEMED + ISP + COFEPRIS + ANVISA + ANMAT + Uruguayan MSP + Paraguayan DNVS + Cuban CECMED harmonised dossier-element reuse alongside national-specific extensions.